MaSTherCell, a subsidiary of Orgenesis Inc., is a cell therapy dedicated Contract Development and Manufacturing Organization. MaSTherCell will perform a technology transfer of FURESTEM-AD’s process and manufacture FURESTEM-AD for Kangstem’s European clinical trial.

“The European clinical trial of Furestem-AD will be a milestone for our company. We believe that MaSTherCell’s expertise and experience will be the key to enable it,” said Mr. Tae Wha Lee, chief executive officer of Kangstem. 

“Kangstem’s allogeneic human umbilical cord blood-derived stem cell based project fits perfectly in MaSTherCell’s long term strategy to provide services across all segments of the cell therapy field,” said Romain de Rauville, business development manager and head of Europe at MaSTherCell. “Being selected by a Korean cell therapy company really portrays MaSTherCell’s expertise and agility in assisting our partners with their globalization. Kangstem’s efficient manufacturing process will further increase MaSTherCell’s expertise and skills to broaden the impact of both companies on the cell therapy field.”